AstraZeneca now sees FY24 core EPS to increase by high teens percentage
The Fly

AstraZeneca now sees FY24 core EPS to increase by high teens percentage

The company said, “Given the strength of underlying Product Sales and Alliance Revenue, as well as increased confidence in achieving certain sales-based milestones, the Company raises its Total Revenue and Core EPS guidance for FY 2024 at CER. Total Revenue is expected to increase by a high teens percentage, previously a mid teens percentage; Core EPS is expected to increase by a high teens percentage, previously a mid teens percentage.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App